Biogen (BIIB) PT Raised to $275 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $249.01 -1.82%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $250.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Marriott International (MAR) PT Raised to $402 at Stifel
- Marvell (MRVL) PT Lowered to $275 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
